propel represents a medical breakthrough clinically proven ... · propel represents a medical...
TRANSCRIPT
PROPEL represents a medical breakthrough clinically proven to improve surgical outcomes for chronic sinusitis sufferers.1
PROPEL is the first and only device clinically shown to keep the sinuses open after surgery, precisely deliver anti-inflammatory medication directly into the healing tissues, and then dissolve. The innovative sinus stent decreases post-operative scarring and inflammation, reducing the need for additional surgical procedures as well as oral steroids1 and their potential side effects. At the same time, PROPEL’s spring-like, lightweight design means patients usually cannot even tell that it is there.
1 Han JK, Marple BF, Smith TL et al. IFAR.2012; 2:271-‐279. The PROPEL sinus implant is intended for use in pa7ents ≥ 18 years of age following ethmoid sinus surgery to maintain the sinus opening. This product is not intended for people who are allergic to the drug (mometasone furoate) or to certain polymers. Safety and effec7veness of the implant in pregnant or nursing females has not been studied. Risks may include pain/pressure, movement of the implant (within or out of the sinus) and possible side effects of the drug. The most common side effects in clinical studies were infec7on, headache and nose bleed. For more informa7on on the risks and benefits of PROPEL, please talk to your doctor. The FDA approved labeling can be found at www.PROPELOPENS.com. Rx only. For addi7onal pa7ent informa7on regarding sinusi7s, visit: www.MySinusi7s.com. ©2016 Intersect ENT, Inc. All rights reserved. INTERSECT and PROPEL are trademarks and registered trademarks of Intersect ENT, Inc. MySinusi7s.com is a trademark of Intersect ENT, Inc. MPM 00114 Rev. B